——
EXCYTE LLC is committed to the R&D and industrialization of monoclonal antibody medicines, multi-functional antibody medicines and CAR-T/TCR-T cell immunotherapy.
EXCYTE antibody humanization technology is based on bioinformatics and small-scale expression combination library to generate humanized sequence combinations with the highest “human” homology.
There are two ways to optimize antibody affinity in EXCYTE: Single point complete randomization combined with hot spot combination pathway (PM) and segment complete block mutation (BM) pathway.
EXCYTE naive antibody phage display library is built by acquiring the PBMC of 25 healthy people from around the world. The donors include Chinese, Japanese, Filipino, Vietnamese, Cambodian, Latin American, Caucasian, Afro American, American Indian, German, Canadian, French, British, Russian, Mongolian etc.
Based on the latest clinical progress, the bispecific antibody platform of EXCYTE, which combins two unique monoclonal antibody into one, has been tested as a novel molecule to realize the activity effect of 1+1>2
Taking ScFv as the main form (which is like the "eye" of a CAR-T), the EXCYTE antibody library provides the tumor specific ScFv and core components for any CAR-T project.
——
EXCYTE offers antibody hits and leads isolation and screening services to any target of interest chosen by customer
——
Excyte Biopharma Ltd, an institution jointly founded by a number of international experts in the field of biomedicine, is committed to the R&D of multi-functional antibody drugs and CAR-T/TCR-T cell immunotherapy
——
Excyte Biopharma Ltd, an institution jointly founded by a number of international experts in the field of biomedicine, is committed to the R&D of multi-functional antibody drugs and CAR-T/TCR-T cell immunotherapy
NHL/ALL免疫治疗候选双抗药物YK012 I期临床试验完成首例受试者给药 2023年5月24日，益科思特（北京）医药科技发展有限公司开发
NHL/ALL免疫治疗候选双抗药物YK012 正式进入I期临床试验阶段2023年5月8日，益科思特（北京）医药科技发展有限公司开发的用于治疗
